Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic Rhinitis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 97
- 试验地点
- 3
- 主要终点
- The primary efficacy endpoint is the change in the global score of the mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) from baseline to week 12 of intervention
研究概览
简要总结
The goal of this clinical trial is to learn if a probiotic formulation consisting of multiple bacterial strains has a positive effect on the quality of life of participants with chronic perennial allergic rhinitis symptoms. The researchers will also study whether the probiotic formulation influences the symptoms of allergic rhinitis. Participants with allergies to house dust mite, cats and/or dogs will be included in the study.
The main questions it aims to answer are:
Does the probiotic formulation have an impact of the quality of life of the participants? Does the probiotic formaluation have an effect on the severity of the symptoms of allergic rhinitis? Are there differences in the effects depending on the allergies the participants have?
Researchers will compare the probiotic formulation to a placebo (a substance that contains no probiotic bacteria but looks, smells, and tastes the same) to see if the probiotic formulation improves the quality of life of participants with chronic allergic rhinitis. In addition, also a GI symptom questionnaire will be filled in by the participants weekly
Participants will visit the clinic for the screening, and at the start, and at the end of the intervention for checkups and sampling. During the intervention they will take the probiotic formulation or a placebo twice every day for 12 weeks. They will keep a diary of their symptoms and note whenever they use anti-histamines and every two weeks they will fill in a questionnaire about their quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged ≥18 years
- •Willing and able to provide informed consent in French
- •Persistent perennial allergic rhinitis induced by a least one perennial allergen in the last two years.
- •Positive skin prick test ≥5 mm for any of the following allergens: cat, dog and mites
- •Mean global score of miniRQLQ ≥ 2
- •TSS score of at least 7
- •Willing to discontinue consumption of fermented foods, probiotics (e.g., yogurts with live, active cultures or supplements), prebiotics or immune-enhancing supplements (e.g., Echinacea or fish oil).
- •Agreement on not starting new medication during the intervention (rescue medication excepted)
- •Women of childbearing potential with a negative pregnancy test throughout the study period and highly effective contraception: oral contraceptives, condom with spermicide, intrauterine device, bilateral tubal ligation, vasectomized partner
排除标准
- •Non-allergic rhinitis
- •Use of any prohibited medication (any systemic corticosteroids, androgens such as testosterone, or high doses of anti-inflammatory drugs: i.e., aspirin in doses 600 mg/d regularly) at the time of enrolment
- •Use of other probiotics-containing and prebiotics-containing products during the intervention period and 4 weeks before study start
- •Use of any antibiotics 6 weeks before randomization
- •Nasal polyposis
- •Currently enrolled in another intervention study (except observational studies)
- •Critically or terminally ill or admitted to the ICU
- •Had received chemotherapy or other immune-suppressing therapy within the previous year.
- •Other conditions that according to the investigator might interfere with the evaluation of the study objectives
- •Patients being treated for or had any of the following physician-diagnosed diseases or conditions: HIV; immune modulating diseases (autoimmune disease, hepatitis, cancer, etc.); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases or conditions, such as diverticulitis, ulcerative colitis, Crohn's disease, Celiac disease, short bowel disease, ileostomy, or colostomy, but not including gastroesophageal reflux disease,
- •Subjects with a low compliance rate (appreciated by the investigator) during the run-in period
研究组 & 干预措施
Probiotic
Participants receive a multispecies probiotic formulation for oral use
干预措施: Multi-species probiotic powder for oral solution. Dietary supplement containing six bacterial strains (Lactobacillus and Bifidobacterium species) (Dietary Supplement)
Placebo
The participants receive a placebo for oral use, comparable in appearance and smell as the probiotic formulation
干预措施: Placebo Powder for Oral Solution (Dietary Supplement)
结局指标
主要结局
The primary efficacy endpoint is the change in the global score of the mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) from baseline to week 12 of intervention
时间窗: From baseline to 12 weeks of intervention
An improvement on quality of life is considered clinically meaningful when improved with ≥0.7 points in global and domain-specific mini-RQLQ scores between intervention and placebo
次要结局
- The impact of intervention in rhino conjunctivitis quality of life will be assessed by the changes in global and domain-specific mini-RQLQ scores from baseline to week 12 of intervention every two weeks.(Every two weeks from baseline to end of treatment at 12 weeks)
- The proportion of participants reporting a clinical relevant improvement on quality of life in global and domain-specific mini-RQLQ scores between intervention and placebo(From baseline to end of treatment at 12 weeks)
- The proportion of participants reporting a clinical relevant improvement on allergic rhinoconjuctivitis symptoms in global and domain-specific TSS scores between intervention and placebo(From baseline to end of treatment at 12 weeks)
- The impact of a multispecies probiotic formulation on allergic rhinoconjunctivitis severity will be assessed by the difference in TSS mean (global and per item) between intervention and placebo over 12 weeks.(From baseline to end of treatment at 12 weeks, daily)
- The impact of a multispecies probiotic formulation on allergic rhinoconjunctivitis severity with established perennial allergies will be assessed as the change in the global score of the TSS from baseline to week 12 of intervention.(From baseline to end of treatment at 12 weeks)
- Differences in TSS will be analysed in subgroups of participants based on type of allergy(From baseline to end of treatment at 12 weeks, daily)
- Differences in TSS will be analysed in subgroups of participants based on allergy pattern(From baseline to end of treatment at 12 weeks, daily)
- Differences in TSS will be analysed in subgroups of participants based on baseline severity of TSS score(From baseline to end of treatment at 12 weeks, daily)
- Differences in mini-RQLQ will be analysed in subgroups of participants based on type of allergy(From baseline to end of treatment at 12 weeks, two weekly)
- Differences in mini-RQLQ will be analysed in subgroups of participants based on allergy pattern(From baseline to end of treatment at 12 weeks, two weekly)
- Differences in mini-RQLQ will be analysed in subgroups of participants based on baseline severity of mini-RQLQ(From baseline to end of treatment at 12 weeks, two weekly)
- Change in immune modulatory biomarkers (cytokines and IgE) at baseline compared to 12 weeks of intervention versus placebo(From baseline to end of treatment at 12 weeks)
- Change in amount of blood cells at baseline compared to 12 weeks of intervention versus placebo(From baseline to end of treatment at 12 weeks)
- Change in ratio of blood cell at baseline compared to 12 weeks of intervention versus placebo(From baseline to end of treatment at 12 weeks)
- Change in rescue medication use (antihistamines) will be expressed as a percentage of the completed daily diary entries over the 12 weeks intervention period(From baseline to end of treatment)
- Reduction in gastro-intestinal complaints will be assessed using the GSRS questionnaire after 12 weeks intervention versus placebo and across weekly time points(From baseline to end of treatment at 12 weeks and weekly between those timepoints)
- Reduction in allergic symptoms other than rhinitis (eczema, food allergy and intolerance) using Non-rhinoconjunctivitis allergy Questionnaire over the 12 weeks intervention versus placebo(From baseline to end of treatment at 12 weeks)
- Change in fecal microbiome profile or metabolites production (e.a SCFA and bile acids) will be analyzed after 12 weeks intervention versus placebo(From baseline to end of treatment at 12 weeks)